Acadia Pharmaceuticals Inc. (ACAD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.60 (+3.61%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Key Insights

Critical company metrics and information
  • Share Price

    $16.62
  • Market Cap

    $2.77 Billion
  • Total Outstanding Shares

    166.39 Million Shares
  • Total Employees

    620
  • Dividend

    No dividend
  • IPO Date

    May 27, 2004
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.acadia.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$60.00 Million
Net Cash Flow From Financing Activities, Continuing$10.31 Million
Net Cash Flow From Investing Activities, Continuing$-153.03 Million
Net Cash Flow From Investing Activities$-153.03 Million
Net Cash Flow From Operating Activities, Continuing$202.73 Million
Net Cash Flow, Continuing$60.00 Million
Net Cash Flow From Operating Activities$202.73 Million
Net Cash Flow From Financing Activities$10.31 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$128.51 Million
Preferred Stock Dividends And Other Adjustments$0.00
Basic Average Shares$2.12 Million
Research and Development$269.26 Million
Operating Expenses$739.07 Million
Net Income/Loss Attributable To Parent$128.51 Million
Selling, General, and Administrative Expenses$469.81 Million
Benefits Costs and Expenses$601.21 Million
Income/Loss From Continuing Operations Before Tax$328.03 Million
Net Income/Loss$128.51 Million
Income Tax Expense/Benefit$8.19 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Gross Profit$851.31 Million
Revenues$929.24 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$128.51 Million
Cost Of Revenue$77.93 Million
Basic Earnings Per Share$0.78
Operating Income/Loss$112.23 Million
Diluted Earnings Per Share$0.78
Diluted Average Shares$2.81 Million
Costs And Expenses$620.90 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Wages$37.02 Million
Liabilities$399.69 Million
Accounts Payable$19.08 Million
Current Liabilities$343.94 Million
Noncurrent Liabilities$55.74 Million
Other Current Liabilities$287.84 Million
Fixed Assets$3.99 Million
Equity Attributable To Parent$577.18 Million
Noncurrent Assets$188.58 Million
Equity Attributable To Noncontrolling Interest$0.00
Prepaid Expenses$51.55 Million
Assets$976.87 Million
Equity$577.18 Million
Other Non-current Assets$184.60 Million
Other Current Assets$649.99 Million
Liabilities And Equity$976.87 Million
Inventory$86.74 Million
Current Assets$788.28 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.